Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs The Travelers Companies Inc. Common Stock (TRV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs The Travelers Companies Inc. Common Stock — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while The Travelers Companies Inc. Common Stock trades at $377.77 (market cap $77.86B). The key difference: The Travelers Companies Inc. Common Stock is far larger — about 80× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and The Travelers Companies Inc. Common Stock pays a 1.34% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and The Travelers Companies Inc. Common Stock for 6 Days on average.
| MRVI | TRV | |
|---|---|---|
Market Cap | $972.90M | $77.86B |
Volume | 4,325,710 | 986,776 |
Sector | Health | Financials |
52-Week High | $9.00 | $397.22 |
52-Week Low | $2.83 | $261.57 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $86.44B |
Dividend Yield | — | 1.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
TRV trades at $373.28, up 0.43% with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 10.03 and ROE of 26.32%, while consistently beating earnings estimates in recent quarters. Recent news highlights Travelers' earnings momentum ahead of Q3 results.
The outlook remains positive given valuation attractiveness and earnings beat history, though risks include competitive pressures and potential earnings volatility. Analyst consensus is mixed with 25% buy ratings but a $353.80 price target below current levels, suggesting cautious optimism.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About The Travelers Companies Inc. Common Stock
The Travelers Companies provides property and casualty insurance for individuals, businesses, and organizations. Its products include auto, home, and commercial coverage.
Read more on TRV →
